Dianthus Therapeutics, Inc. /DE/ Unbilled Receivables, Current
Dianthus Therapeutics, Inc. /DE/ (DNTH) had Unbilled Receivables, Current of $519.00 thousand as of 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:UnbilledReceivablesCurrent · last filed 2023-12-21
- 2023-09-30: Unbilled Receivables, Current $519.00K.
- 2022-12-31: Unbilled Receivables, Current $938.00K.
- 2021-12-31: Unbilled Receivables, Current $1.01M.
| Period end | Unbilled Receivables, Current |
|---|---|
| 2023-09-30 | $519.00K 10-Q · filed 2023-11-09 |
| 2022-12-31 | $938.00K 8-K · filed 2023-12-21 |
| 2021-12-31 | $1.01M 8-K · filed 2023-12-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |